株式会社極東書店トップ商品一覧Statistical Methods for Immunogenicity Assessment.

商品詳細

Statistical Methods for Immunogenicity Assessment.

Statistical Methods for Immunogenicity Assessment.

・ISBN 978-0-367-73797-9 paper GB£ 53.99

¥17,103.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り
電子版あり 大学・学術機関向け電子ブック(eBook)ISBN 9780429160424
著者・編者Yang, Harry / Zhang, Jianchun / Yu, Binbing / Zhao, Wei,
シリーズ (Chapman & Hall/CRC Biostatistics Series)
出版社 (Chapman & Hall/CRC, UK)
出版年月2020
ページ数259 pp.
言語ENG
ニュース番号<A00-45006>

解説

Develop Effective Immunogenicity Risk Mitigation Strategies

Immunogenicity assessment is a prerequisite for the successful development of biopharmaceuticals, including safety and efficacy evaluation. Using advanced statistical methods in the study design and analysis stages is therefore essential to immunogenicity risk assessment and mitigation strategies. Statistical Methods for Immunogenicity Assessment provides a single source of information on statistical concepts, principles, methods, and strategies for detection, quantification, assessment, and control of immunogenicity.

The book first gives an overview of the impact of immunogenicity on biopharmaceutical development, regulatory requirements, and statistical methods and strategies used for immunogenicity detection, quantification, and risk assessment and mitigation. It then covers anti-drug antibody (ADA) assay development, optimization, validation, and transfer as well as the analysis of cut point, a key assay performance parameter in ADA assay development and validation. The authors illustrate how to apply statistical modeling approaches to establish associations between ADA and clinical outcomes, predict immunogenicity risk, and develop risk mitigation strategies. They also present various strategies for immunogenicity risk control. The book concludes with an explanation of the computer codes and algorithms of the statistical methods.

A critical issue in the development of biologics, immunogenicity can cause early termination or limited use of the products if not managed well. This book shows how to use robust statistical methods for detecting, quantifying, assessing, and mitigating immunogenicity risk. It is an invaluable resource for anyone involved in immunogenicity risk assessment and control in both non-clinical and clinical biopharmaceutical development.